Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00264108|
Recruitment Status : Completed
First Posted : December 12, 2005
Last Update Posted : May 7, 2014
|Condition or disease||Intervention/treatment|
|Anemia Neoplasms||Drug: Darbepoetin alfa Drug: Epoetin alfa|
|Study Type :||Observational|
|Actual Enrollment :||492 participants|
|Official Title:||EPREX (Epoetin Alfa) Versus ARANESP (Darbepoetin Alfa): Looking at Outcome of Anemia Treatment and Comparing Cost-effectiveness (EVALUATE).|
|Study Start Date :||June 2005|
|Actual Primary Completion Date :||February 2011|
|Actual Study Completion Date :||February 2011|
Epoetin alfa 40 000 IU once weekly variable treatment length.
Drug: Epoetin alfa
40,000 IU once weekly, variable treatment length.
Darbepoetin alfa Either 150 ug once weekly or 500 ug once every 3 wks variable treatment length.
Drug: Darbepoetin alfa
Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.
- Cost-effectiveness based on: cancer type and status, chemotherapy and other anti-cancer treatment, hemoglobin levels, use of either epoetin alfa or darbepoetin alfa, use of blood transfusions, serum iron levels and iron supplementation. [ Time Frame: 4 weeks, 8 weeks and end of treatment ]
- Safety evaluations including the incidence of serious and non-serious adverse events. [ Time Frame: from start of (Darb)epoetin treatment to end of study. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00264108
|Bergen Op Zoom, Netherlands|
|Den Helder, Netherlands|
|Ede Gld, Netherlands|
|Study Director:||Janssen-Cilag B.V. Clinical Trial||Janssen-Cilag B.V.|